GRCE (Grace Therapeutics) Common Stock: $0.00 Mil (As of Mar. 2026)


GRCE Grace Therapeutics Inc GRCE
31 GF Score
Price $2.10
! 2 Warning Signs
View Full Analysis

What is Grace Therapeutics Common Stock?

Grace Therapeutics GRCE -10.64% 31 Common Stock is $0.00 Mil as of Mar. 2026. GuruFocus rates GRCE with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

Grace Therapeutics's quarterly common stock stayed the same from Sep. 2025 ($0.00 Mil) to Dec. 2025 ($0.00 Mil) and stayed the same from Dec. 2025 ($0.00 Mil) to Mar. 2026 ($0.00 Mil).

Grace Therapeutics's annual common stock stayed the same from Mar. 2024 ($0.00 Mil) to Mar. 2025 ($0.00 Mil) and stayed the same from Mar. 2025 ($0.00 Mil) to Mar. 2026 ($0.00 Mil).

Grace Therapeutics Common Stock Historical Data

* Premium members only.

The historical data trend for Grace Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Grace Therapeutics Common Stock Chart

Grace Therapeutics Annual Data
Trend Feb16 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 257.99 258.29 0.00 0.00 0.00

Grace Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
GRCE
31GF Score
Grace Therapeutics Inc GRCE
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Grace Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $0.00 Mil mean?
Grace Therapeutics (GRCE) has a Common Stock of $0.00 Mil as of Mar. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Grace Therapeutics and its competitors.
Is Grace Therapeutics' Common Stock too high?
Grace Therapeutics' current Common Stock is $0.00 Mil. Overall, Grace Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Grace Therapeutics' Common Stock compare to INMB and ABVC?
Grace Therapeutics' Common Stock of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Grace Therapeutics and its competitors. Grace Therapeutics's current Common Stock is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grace Therapeutics stock overvalued right now?
Grace Therapeutics (GRCE) has a current Common Stock of $0.00 Mil. The current Common Stock is $0.00 Mil. Grace Therapeutics' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Grace Therapeutics (GRCE), the current Common Stock is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Grace Therapeutics Business Description

Address 103 Carnegie Center, Suite 300, Princeton, NJ, USA, 08540
Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.
31GF Score

Get the complete analysis for GRCE

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.10
Price